New shot aims to slash dangerous cholesterol in teens with rare genetic disease
NCT ID NCT07473843
First seen Mar 16, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests an experimental drug called zodasiran in 12 teenagers (ages 12 to 17) with homozygous familial hypercholesterolemia, a rare genetic condition causing extremely high cholesterol. Participants receive injections of zodasiran to see if it safely lowers their LDL cholesterol over 12 months. All teens are already on maximum tolerated cholesterol-lowering treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.